A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 8, 2007, Pages 956-964

  Sabloff, Mitchell ^a   Atkins, Harold L ^a   Bence Bruckler, Isabelle ^a   Bredeson, Christopher ^a   Fergusson, Dean ^a   Genest, Paul ^a   Hopkins, Harry ^a   Hutton, Brian ^a   Mcdiarmid, Sheryl ^a   Huebsch, Lothar B ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Autologous stem cell transplant; Follicular; Lymphoma; Radiation; Relapse; Transformed

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETREATMENT; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONTARIO; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 34447316474     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.009     Document Type: Article

References (53)

1. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
2. Horning S.J. High-dose therapy and transplantation for low-grade lymphoma. Hematol Oncol Clin N Am 11 (1997) 919-935
3. Horning S.J. Follicular lymphoma: have we made any progress?. Ann Oncol 11 Suppl 1 (2000) 23-27
4. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 (1984) 1471-1475
5. Neri N., Aviles A., Cleto S., et al. Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. J Hematother Stem Cell Res 10 (2001) 669-674
6. Zinzani P.L., Pulsoni A., Perrotti A., et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22 (2004) 2654-2661
7. Baldini L., Brugiatelli M., Luminari S., et al. Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 21 (2003) 1459-1465
8. Young R.C., Longo D.L., Glatstein E., et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (1988) 11-16
9. Klasa R.J., Meyer R.M., Shustik C., et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. [see comment]. J Clin Oncol 20 (2002) 4649-4654
10. Santoro A., Balzarotti M., Tondini C., et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 519-525
11. Yung L., Cunningham D., Hancock B., et al. Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI). Br J Cancer 91 (2004) 695-698
12. Dana B.W., Dahlberg S., Nathwani B.N., et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11 (1993) 644-651
13. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13 (1995) 140-147
14. Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4 (1986) 1470-1480
15. Bastion Y., Sebban C., Berger F., et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15 (1997) 1587-1594
16. Yuen A.R., Kamel O.W., Halpern J., and Horning S.J. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13 (1995) 1726-1733
17. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
18. Philip T., Biron P., Philip I., et al. Massive therapy and autologous bone marrow transplantation in very bad prognosis Burkitt's lymphoma (1985), IARC Scientific Publications, Lyon, France 419-434
19. Appelbaum F.R., Deisseroth A.B., Graw Jr. R.G., et al. Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 41 (1978) 1059-1063
20. Philip T., Biron P., Herve P., et al. Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis. Eur J Cancer Clin Oncol 19 (1983) 1371-1379
21. Frei E., and Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 69 (1980) 585-594
22. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
23. Colombat P., Cornillet P., Deconinck E., et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant 26 (2000) 971-977
24. Apostolidis J., Gupta R.K., Grenzelias D., et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18 (2000) 527-536
25. Gonzalez-Barca E., Fernandez d.S., Domingo-Claros A., et al. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant 26 (2000) 1051-1056
26. Berglund A., Enblad G., Carlson K., Glimelius B., and Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 65 (2000) 17-22
27. Corradini P., Ladetto M., Zallio F., et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 22 (2004) 1460-1468
28. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
29. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11 (2000) 1585-1590
30. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
31. Schouten I.C., Raemaekers J.J., Kluin-Nelemans H.C., et al., Dutch HOVON Group. High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin's lymphoma. Ann Hematol 73 (1996) 273-277
32. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
33. Foran J.M., Apostolidis J., Papamichael D., et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. [see comment]. Ann Oncol 9 (1998) 865-869
34. Schouten H.C., Bierman P.J., Vaughan W.P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74 (1989) 2579-2584
35. Bastion Y., Brice P., Haioun C., et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86 (1995) 3257-3262
36. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19 (2001) 727-735
37. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80 (1992) 2142-2148
38. Apostolidis J., Foran J.M., Johnson P.W., et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 17 (1999) 216-221
39. Caballero M.D., Rubio V., Rifon J., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20 (1997) 451-458
40. Mills W., Chopra R., McMillan A., et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13 (1995) 588-595
41. Gratwohl A., Baldomero H., Schmid O., et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant 36 (2005) 575-590
42. Seyfarth B., Kuse R., Sonnen R., et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?. Ann Hematol 80 (2001) 398-405
43. Bierman P.J., Vose J.M., Anderson J.R., et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 445-450
44. Decaudin D., Lepage E., Brousse N., et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 17 (1999) 2499-2505
45. Laudi N., Arora M., Burns L.J., et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 129-135
46. Cao T.M., Horning S., Negrin R.S., et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 7 (2001) 294-301
47. Rohatiner A.Z., Johnson P.W., Price C.G., et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12 (1994) 1177-1184
48. Metayer C., Curtis R.E., Vose J., et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101 (2003) 2015-2023
49. Darrington D.L., Vose J.M., Anderson J.R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12 (1994) 2527-2534
50. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. [see comment]. Blood 102 (2003) 2351-2357
51. Fisher R.I., LeBlanc M., Press O.W., et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23 (2005) 8447-8452
52. Stone R.M. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 83 (1994) 3437-3440
53. Miller J.S., Arthur D.C., Litz C.E., et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83 (1994) 3780-3786